IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.

About IsoPlexis

IsoPlexis is the Superhuman Cell company.

By leading the discovery and identification of how multi-functional immune— Superhuman— cells communicate and respond, IsoPlexis assists researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and at over 70% of leading U.S. comprehensive cancer centers.

Investor Contact
investors@isoplexis.com

Press Contact
press@isoplexis.com

Staff

Recent Posts

Fangzhou Launches Otsuka’s Third-Generation Leukemia Drug Ponatinib on its Platform

GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in…

60 minutes ago

SprintRay Appoints Dr. Meena Barsoum as Global Head of Clinical Strategy

LOS ANGELES, May 5, 2025 /PRNewswire/ -- SprintRay, the global leader in dental 3D printing,…

60 minutes ago

FendX Announces Share Issuance Pursuant to IP License Agreement

Oakville, Ontario--(Newsfile Corp. - May 5, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

5 hours ago

The Lens Magazine Features Joe Kiani, Willow Laboratories Founder and Nutu Visionary, on Cover of Latest Issue Following LSI USA ‘25 Keynote

DANA POINT, Calif.--(BUSINESS WIRE)--The Lens, LSI’s executive-focused medtech magazine, proudly unveils Volume 2, Edition 3,…

7 hours ago

eMed Announces Collaboration with Aon to Provide a Digital GLP-1 Benefit Program for Aon colleagues

Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity management MIAMI, May 5, 2025 /PRNewswire/ -- eMed®,…

7 hours ago